PUMA Biotechnology (PBYI) director gets 27,000-share award, sells 22,000 shares

Rhea-AI Filing Summary

PUMA Biotechnology director Jay M. Moyes reported both an equity grant and a share sale. On June 11, 2026, he received 27,000 shares as a grant described as Restricted Stock Units that vest in full on the earlier of the one-year anniversary of grant or the next annual shareholder meeting, subject to continued service.

On June 12, 2026, he sold 22,000 shares of common stock in an open-market transaction pursuant to a Rule 10b5-1(c) trading plan adopted on March 12, 2025, at a weighted-average price of $7.218 per share across trades ranging from $6.98 to $7.32. Following these transactions, he directly holds 58,322 shares of common stock.

Insights

Equity compensation and insider-trading analyst

Director received 27,000-share equity award, then sold 22,000 shares under a pre-set 10b5-1 plan.

The filing shows a typical compensation-and-liquidity pattern. Director Jay M. Moyes was granted 27,000 Restricted Stock Units that vest after roughly one year or at the next annual shareholder meeting, contingent on continued board service.

The next day he sold 22,000 common shares at a weighted-average $7.218 under a pre-existing Rule 10b5-1(c) trading plan adopted on March 12, 2025. Because 10b5-1 plans are pre-arranged, the timing of these sales carries limited informational value about his current view of the stock.

After the grant and sale, he directly owns 58,322 shares, indicating he retains a meaningful equity stake. Subsequent company filings may show future RSU vesting or additional 10b5-1 transactions, which together outline his longer-term equity exposure.

Insider Trade Summary 10b5-1

Net Seller: 22,000 shares ($158,796)

Net Sell 2 txns

Insider MOYES JAY M

Role null

Sold 22,000 shs ($159K)

Type	Security	Shares	Price	Value
Sale	Common Stock	22,000	$7.218	$159K
Grant/Award	Common Stock	27,000	$0.00	--

Holdings After Transaction: Common Stock — 58,322 shares (Direct, null)

Footnotes (1)

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 22,000 shares Weighted-average sale price: $7.218 per share Price range of sales: $6.98 to $7.32 +3 more

6 metrics

Shares sold 22,000 shares Open-market sale on June 12, 2026

Weighted-average sale price $7.218 per share Sale of 22,000 shares on June 12, 2026

Price range of sales $6.98 to $7.32 Multiple sale transactions on June 12, 2026

Equity award size 27,000 shares Restricted Stock Unit grant on June 11, 2026

Post-transaction holdings 58,322 shares Direct common stock ownership after reported transactions

10b5-1 plan adoption date March 12, 2025 Plan governing the June 12, 2026 share sale

Key Terms

Restricted Stock Units, Rule 10b5-1(c) plan, weighted average price, open-market sale

4 terms

Restricted Stock Units financial

"Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1(c) plan regulatory

"Adoption date of referenced 10b5-1(c) plan is: 03-12-2025"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOYES JAY M

(Last) (First) (Middle)

C/O PUMA BIOTECHNOLOGY, INC.

10880 WILSHIRE BOULEVARD, SUITE 1700

(Street)

LOS ANGELES CALIFORNIA 90024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PUMA BIOTECHNOLOGY, INC. [ PBYI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		27,000	A	$0(1)	80,322	D
Common Stock	06/12/2026		S(2)		22,000	D	$7.218(3)	58,322	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.

2. Adoption date of referenced 10b5-1(c) plan is: 03-12-2025

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Gordon Esplin as attorney-in-fact for Jay M. Moyes	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did PUMA Biotechnology (PBYI) director Jay Moyes report?

Jay M. Moyes reported two transactions: a grant of 27,000 shares, described as Restricted Stock Units, on June 11, 2026, and an open-market sale of 22,000 common shares on June 12, 2026, leaving him with 58,322 shares directly held.

How many PUMA Biotechnology (PBYI) shares did Jay Moyes sell and at what price?

He sold 22,000 shares of PUMA Biotechnology common stock on June 12, 2026, at a weighted-average price of $7.218 per share. The trades occurred in multiple lots with prices ranging from $6.98 to $7.32, according to the filing footnote.

Was the PUMA Biotechnology (PBYI) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted on March 12, 2025. Such pre-arranged plans allow insiders to systematically sell shares over time according to predetermined instructions, reducing discretion over trade timing.

What equity award did PUMA Biotechnology (PBYI) grant to director Jay Moyes?

He received 27,000 shares as a grant described as Restricted Stock Units. These units vest in full on the earlier of the one-year anniversary of the grant date or the next annual shareholder meeting, provided he continues his service with PUMA Biotechnology through that vesting date.

How many PUMA Biotechnology (PBYI) shares does Jay Moyes own after these transactions?

After the June 11, 2026 grant and the June 12, 2026 sale, Jay M. Moyes directly holds 58,322 shares of PUMA Biotechnology common stock. This figure, disclosed in the Form 4, reflects his direct ownership position immediately following the reported transactions.